The Journal of Liquid Biopsy, Journal Year: 2025, Volume and Issue: unknown, P. 100293 - 100293
Published: March 1, 2025
Liquid biopsy (LB) has emerged as a transformative tool in oncology, providing minimally invasive approach for tumor detection, molecular characterization, and real-time treatment monitoring. By analyzing circulating DNA (ctDNA), cells (CTCs), extracellular vesicles (EVs), microRNA (miRNA), LB enables comprehensive profiling without the need traditional tissue biopsies. Over past decade, research this field expanded exponentially, leading to integration of into clinical practice specific cancer types, including lung breast cancer. In 2024, Journal Biopsy (JLB) published innovative studies exploring latest advancements technologies, biomarkers, their applications minimal residual disease (MRD) monitoring, therapy response assessment. This review synthesizes recent findings on role monitoring across different with particular focus newly context within translational research. Additionally, it highlights emerging techniques such fragmentomics, artificial intelligence, multiomics, paving way more precise, personalized decisions. Despite these advancements, challenges remain standardizing methodologies, optimizing validation, integrating routine oncological workflows. mini-review evolving landscape its potential revolutionize diagnosis, therapeutic decision-making, ushering new era precision oncology.
Language: Английский